Caribou Biosciences (CRBU) Cash & Equivalents (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Cash & Equivalents data on file, last reported at $12.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 59.01% year-over-year to $12.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.1 million (down 59.01% YoY) and the FY2025 annual result came in at $12.4 million, down 24.14% from the prior year.
• Cash & Equivalents fell to $12.1 million in Q1 2026 per CRBU's latest filing, from $12.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $147.6 million in Q1 2022 and bottomed at $11.1 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $49.4 million (2024), against an average of $52.9 million.
• Peak annual rise in Cash & Equivalents reached 243695.65% in 2022, while the deepest fall reached 81.14% in 2022.
• Tracing CRBU's Cash & Equivalents over 5 years: stood at $58.3 million in 2022, then decreased by 12.3% to $51.2 million in 2023, then sank by 68.15% to $16.3 million in 2024, then slipped by 24.14% to $12.4 million in 2025, then declined by 2.45% to $12.1 million in 2026.
• Per Business Quant, the three latest CRBU Cash & Equivalents figures stand at $12.1 million (Q1 2026), $12.4 million (Q4 2025), and $11.1 million (Q3 2025).

Peer Comparison